Brevan Howard Capital Management LP Acquires 1,339 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Brevan Howard Capital Management LP raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 36.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,985 shares of the biotechnology company’s stock after buying an additional 1,339 shares during the period. Brevan Howard Capital Management LP’s holdings in Sarepta Therapeutics were worth $606,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Capital International Investors raised its holdings in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Norges Bank bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $126,315,000. Alkeon Capital Management LLC lifted its holdings in Sarepta Therapeutics by 34.7% during the 4th quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company’s stock worth $103,819,000 after purchasing an additional 220,000 shares during the last quarter. Brandywine Global Investment Management LLC bought a new stake in Sarepta Therapeutics in the 4th quarter valued at $22,613,000. Finally, Northern Trust Corp grew its holdings in Sarepta Therapeutics by 22.6% in the 4th quarter. Northern Trust Corp now owns 803,511 shares of the biotechnology company’s stock valued at $97,699,000 after buying an additional 147,874 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT stock opened at $36.27 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 52-week low of $35.46 and a 52-week high of $173.25. The company has a market capitalization of $3.56 billion, a P/E ratio of 29.02 and a beta of 0.85. The company has a fifty day moving average price of $66.84 and a 200-day moving average price of $100.86.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The company had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same period in the previous year, the firm posted $0.73 earnings per share. The firm’s quarterly revenue was up 80.2% compared to the same quarter last year. As a group, equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SRPT shares. The Goldman Sachs Group reduced their target price on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday. Evercore ISI lowered shares of Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price on the stock. in a research report on Thursday. Wells Fargo & Company dropped their price target on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday. Piper Sandler lowered their price objective on Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Morgan Stanley cut their target price on Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating for the company in a research report on Wednesday. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $131.22.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.